Table 1.

Patient and tumor characteristics in relation to histological markers^a

Characteristic	% Patients with the following PDCs:				% Patients with the following TB:				% Patients with the following PN:				% Patients with the following CLR:			% Patients with the following DRb:
	G1	G2	G3	P	G1	G2	G3	P	Absent	Intra	Extra	P	Absent	Present	P	Mature	Intermed	Immature	P
Total	68.3	17.0	14.7		70.4	17.7	11.9		71.6	20.3	8.1		75.2	24.8		58.6	30.4	11.0
Sex				0.39				0.75				0.30			0.024				0.12
Male	49.1	42.8	48.8		48.6	47.7	44.6		48.9	48.0	39.1		50.2	41.2		48.2	51.3	36.8
Female	50.9	57.2	51.2		51.4	52.3	55.4		51.1	52.0	60.9		49.8	58.8		51.8	48.7	63.2
Age				0.11				0.14				0.002			0.22				0.72
>65 yr	53.2	53.8	43.2		53.9	48.3	44.6		55.2	46.8	34.8		50.6	55.5		51.5	54.6	51.0
≤65 yr	46.8	46.2	56.8		46.1	51.7	55.4		44.8	53.2	65.2		49.4	44.5		48.5	45.4	49.0
Site of primary tumor				0.003				0.090				0.007			<0.0001				0.040
Right colon	57.0	44.1	44.8		55.4	47.7	46.5		56.2	42.8	50.7		50.5	36.5		50.7	61.0	47.1
Left colon	43.0	55.9	55.2		44.6	52.3	53.5		43.8	57.2	49.3		49.5	63.5		49.3	39.0	52.9
CEA				0.002				<0.001				<0.001			0.31				<0.001
>5.0 ng/mL	30.4	35.9	47.4		30.1	38.3	48.9		31.3	33.3	57.1		32.8	36.7		34.2	43.1	60.3
≤5.0 ng/mL	69.6	64.1	52.6		69.9	61.7	51.1		68.7	66.7	42.9		67.2	63.3		65.8	56.9	39.7
T stage				<0.001				<0.001				<0.001			<0.0001				<0.001
T1	11.4	5.5	2.4		11.9	2.6	2.0		11.5	4.1	0.0		10.2	5.7
T2	21.7	15.2	8.0		21.5	15.9	5.0		22.3	12.7	0.0		20.5	12.8
T3	60.9	62.1	60.8		61.6	62.3	56.4		59.3	64.7	68.1		55.8	77.3		92.5	78.6	57.4
T4	6.0	17.2	28.8		5.0	19.2	36.6		6.9	18.5	31.9		13.6	4.3		7.5	21.4	42.7
N stage				<0.001				<0.001				<0.001			0.075				<0.001
N0	74.9	47.6	33.6		75.0	45.0	28.7		72.3	50.3	27.5		62.0	70.6		66.8	48.1	27.9
N1	18.6	38.6	38.4		18.7	36.4	44.6		21.5	30.6	40.6		26.6	19.9		24.1	34.2	41.2
N2	6.5	13.8	28.0		6.3	18.5	26.7		6.2	19.1	31.9		11.4	9.5		9.1	17.7	30.9
AJCC stage (5th ed.)				<0.001				<0.001				<0.001			<0.001				<0.001
I	29.1	14.5	4.8		29.2	12.6	2.0		29.1	11.0	0.0		25.5	15.6
II	45.8	33.1	28.8		45.7	32.5	26.7		43.2	39.3	27.5		36.6	55.0		66.8	48.1	27.9
III	25.1	52.4	66.4		25.0	55.0	71.3		27.8	49.7	72.5		38.0	29.4		33.2	51.9	72.1
WHO grade				<0.001				<0.001				<0.001			0.74				0.005
1	3.1	0.7	0.0		3.2	0.0	0.0		3.0	0.6	0.0		2.2	2.4		2.2	0.0	0.0
2	86.8	87.6	56.0		86.8	82.8	55.4		86.5	74.0	66.7		81.9	83.9		83.9	79.1	72.1
3	10.2	11.7	44.0		10.0	17.2	44.6		10.5	25.4	33.3		15.9	13.7		13.9	20.9	27.9
LVI				<0.001				<0.001				<0.001			0.11				<0.001
Yes	34.4	64.1	81.6		33.9	70.2	85.1		36.5	65.9	85.5		48.0	41.7		41.8	64.2	92.7
No	65.6	35.9	18.4		66.1	29.8	14.9		63.5	34.1	14.5		52.0	58.3		58.2	35.8	7.4
Median no. of TILs/5 HPF (IQR)	6 (2–18)	3 (1–7)	1 (0–4)	<0.001	6 (2–19)	3 (1–6)	1 (0–3)	<0.001	5 (1–16)	2 (0–9)	1 (0–5)	<0.001	3 (1–9)	10 (2–29)	<0.001	5 (1–14)	2 (0–7)	1 (0–3)	<0.001
Peritumoral lymphocytes				<0.001				<0.001				<0.001			<0.001				<0.001
Yes	62.1	45.5	32.8		63.9	40.4	23.8		60.4	47.4	26.1		47.8	76.8		55.1	49.2	13.2
No	37.9	54.5	67.2		36.1	59.6	76.2		39.6	52.6	73.9		52.2	23.2		44.9	50.8	86.8
MMR proteinc				0.005				0.001				<0.001			<0.001				0.046
Intact	72.5	86.5	86.4		71.7	90.7	91.1		71.6	87.4	91.7		84.4	58.8		73.1	78.2	91.7
Deficient	27.5	13.5	13.6		28.3	9.3	8.9		28.4	12.6	8.3		15.6	41.2		26.9	21.8	8.3

^aP values were calculated using the Mann-Whitney U test for continuous variables and the χ² test for categorical variables.

Intra, intramural; Extra, extramural; Intermed, intermediate; CEA, carcinoembryonic antigen; WHO, World Health Organization; LVI, lymphovascular invasion; TILs, tumor infiltrating lymphocytes; HPF, high power field; IQR, interquartile range; MMR, mismatch repair.

^bApplicable for T3/4 tumors only (n=616).

^cApplicable for patients who underwent MMR testing only (n=445)